Australia's Lumos Diagnostics after securing full medicare reimbursement recognition

Lumos Diagnostics Holdings

21/11/2025 05:00

** Shares of Lumos Diagnostics LDX.AX rise as much as 15.8% to A$0.22, their highest level since November 13

** Healthcare diagnostics provider secures 100% medicare reimbursement recognition for FebriDx from all Medicare Administration Contractors at US$41.38 per test

** FebriDx is a rapid point-of-care test that uses blood samples to aid in the differentiation between bacterial and non-bacterial infection

** Shares up 514.3% YTD, including day's moves

(Reporting by Aamir Sheik Khalid in Bengaluru)

((mailto: Aamir.SheikKhalid@thomsonreuters.com))